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Background: Optimal antimicrobial stewardship (AMS)
requires adequate technical knowledge of subjects including phar-
macology, microbiology and infection prevention, and improved
knowledge of antimicrobial resistance was highlighted as a
strategic aim in the recent United Kingdom (UK) Antimicrobial
Resistance Strategy.
Undergraduate students appear interested in receiving
increased antimicrobial education, but there is limited evidence
on their views about AMS. Recognising the multidisciplinary use
of antimicrobials, we explored the educational content delivered
in undergraduate health and veterinary sciences in the UK.
Methods&Materials:All UK higher education institutionswith
medicine, nursing, pharmacy, dentistry or veterinary undergrad-
uate courses were identiﬁed from the Universities and Colleges
Admission Service (UCAS) list. Module leaders and/or course orga-
nizers were invited to participate in an anonymous, web-based
electronic survey exploring the AMS content in their curricula. Ele-
ments of optimal AMS are described in Box 1. Responses were
analysed using descriptive statistics.
Results: 112/136 (82%) UK universities responded. AMS was
explicitly incorporated in most curricula (88/112, 79%, no data for
3 universities), with some variation amongst disciplines (dentistry
100%; medicine 96%; veterinary 96%; pharmacy 87%; nursing 63%).
Of 88 universities reporting AMS in their curricula, 63 (72%) pro-
vided the number of hours, reﬂecting variation as well (medicine
41.8 ± 67.6; veterinary 37.6 ± 49; pharmacy 21.2 ± 28; nursing
19.8 ± 42.1; dentistry 8.4 ± 4.8, Kruskal-Wallis H= 9.134, 4 d.f.,
P=0.0578).
All AMS elements were discussed in 36% (32/88) universities,
ranging from 67% (medicine) to 13% (nursing). Maintaining infec-
tion control precautions was most frequently taught (94%, 83/88),
followedbyminimisation of unnecessary antimicrobial prescribing
(72/88, 82%); on the other hand, therapeutic drug monitoring and
IV-to-oral switch were reported in ∼50% of courses.
Conclusion: Whilst AMS is explicitly incorporated in most UK
health and veterinary undergraduate courses, educatorsmay avoid
the fragmentation suggested in our study by considering AMS as
a bundle of optimal antimicrobial prescribing practices. The vari-
ability in hours and content delivered in UK universities merits
further exploration. Continued education initiatives for graduates
may need to strengthen the aspects such as ‘IV-to-oral’ switch less
frequently discussed in undergraduate education.
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Efﬁcacy and safety of oral fosfomycin for
urinary tract infections (UTIs) in hospitalized
patients
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Background: Treatment of inpatient UTIs is complex. Urinary
pathogens are often resistant to multiple agents, and some com-
monly used agents (especially the ﬂuoroquinolones) predispose to
C. difﬁcile infection (CDI) andpromote resistance. Oral fosfomycin, a
phosphonic acid derivative, is a relatively nontoxic UTI agent occa-
sionally used for inpatient UTI treatment despite limited data in
this population.
Methods&Materials:We retrospectively reviewed the records
of all inpatients who had received oral fosfomycin therapy for UTIs.
Patients who were discharged within 48hours of receiving fos-
fomycin were excluded. Charts were reviewed for demographics,
comorbid conditions, urologic abnormalities, culture results, and
clinical outcomes. UTI “cure” was deﬁned as resolution of symp-
toms (dysuria, frequency, urgency) and signs (fever, elevatedWBC),
with no need for retreatment or re-isolation of the same organism
within 30 days.
Results: 71 patients were included. The median age was 75
(range24-98years). 28 (39%)haddiabetes, 15 (21%)had renal insuf-
ﬁciency, and 27 (38%) had undergone a recent urologic procedure.
Most (73%) had received systemic antibiotics in the preceding 2
weeks. 36 (51%) received additional antibiotics during fosfomycin
therapy, often for concurrent non-urinary tract infections. Urinary
isolates included 40 enteric Gram-negative rods of which 9 were
ESBLs, 14 enterococci, and 9 Pseudomonas aeruginosa; some cul-
tures were mixed. Fosfomycin susceptibilities were performed on
24 isolates; 3 were intermediate and 3 resistant. 59 patients (83%)
were cured. Of remaining patients, 2 (4%) overtly failed, 4 (6%)were
changed to another antimicrobial for UTI treatment after in vitro
fosfomycin resistance was reported, and 5 (7%) could not be fairly
evaluated because of continuing therapy of other infectious condi-
tionsor inadequate follow-updata. 5patientsdevelopedCDIwithin
30 days of fosfomycin therapy, but all were exposed to other sys-
temic antimicrobials. Toxicity was reported in 3 patients, but side
effects were mild (nausea, diarrhea).
